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Introduction 
AJ>olipoprotein E 
Apolipoprotein E (apoE) is a 34-kDa protein component of many lipoproteins 
including very low-density lipoproteins (VLDL ), chylomicrons, and high density 
lipoproteins. ApoE plays a major role in their metabolism by mediating high-affinity 
binding oflipoproteins to receptors (Mahley, 1998). Receptor-lipoprotein binding 
initiates cellular uptake and degradation of the lipoproteins, making the lipid available for 
intracellular metabolism. ApoE therefore, serves as a ligand for the receptor-mediated 
clearance oflipoproteins from the plasma (Rall et al., 1982). 
The apoE gene is located on chromosome 19 and contains 3597 nucleotides and 
four exons. ApoE is encoded by an 1163 nucleotide mRNA (Mahley, 1988). In humans, 
there are three common isoforms of apoE. The most common isoform is apoE3, which 
contains cysteine and arginine at positions 112 and 158, respectively. Both positions 
contain cysteine in apoE2 and arginine in apoE4 (Weisgraber, 1994). The allele 
frequencies found in several populations are as follows: 0.07 for apoE2, 0.78 for apoE3, 
and 0.14 for apoE4 (Hallman et al., 1991). 
Role of apoE in the Nervous System 
ApoE is the major apolipoprotein in the brain and cerebrospinal fluid (CSF) with 
astrocytes being the major apoE producing cells in the brain (Pitas et al., 1987). 
Microglia also produce apoE in the central nervous system (CNS) (Nathan et al., 2001). 
Neurons are not known to secrete apoE (Pitas et al., 1987). Among CSF lipoproteins, 
apoE is the only apolipoprotein that can interact with lipoprotein receptors. Cells within 
the brain express four receptors for apoE-containing lipoproteins: low density lipoprotein 
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(LDL) receptor, LDL receptor-related protein (LRP), VLDL receptor, and glycoprotein 
(gp) 330. The LDL receptor and LRP receptor are expressed by neurons (Pitas et al., 
1987; Boyles et al., 1985). It has been shown that some neurons express the VLDL 
receptor, and that ependymal cells express the gp330 receptor (W"tllnow et al., 1992; 
Sakai et al., 1994; Kim et al.; 1996 & Kounnas et al., 1994). It has been reported that the 
LDL receptor and LRP receptor mediate the binding and internalization of apoE-
containing lipoproteins in cultured neurons (Bellosta et al., 1995). These studies provide 
evidence that the apoE and apoE-containing lipoproteins are present within the brain 
where they can interact with neurons and that lipoprotein transport by apoE is important 
for normal functioning of adult neurons. 
Studies of apoE in the maintenance and repair of peripheral nervous system (PNS) 
and CNS nerves have provided clues to its function. In a rat model, the synthesis of apoE 
increases 250- to 350-fold following peripheral nerve injury (Ignatius et al., 1986; Snipes 
et al., 1986). This enormous increase of apoE is thought to play a key role in recycling 
lipids from the degenerating axonal and myelin membranes for use by regenerating axons 
and myelin sheaths. Similarly, induction of apoE synthesis has also been observed in the 
central nervous system following optic nerve and spinal cord injury (Ignatius et al., 1986; 
Messmer et al., 1996; Snipes et al., 1986). Studies on apoE-deficient mice showed fewer 
synapses, vacuolized and swollen dendrites, and a reduced recovery following perforant 
pathway lesions (Masliah et al., 1995; Masliah et al., 1996; Masliah et al., 1997). 
Conversely, studies from other laboratories did not observe any significant morphological 
abnormalities in apoE gene knockout (KO) mice (Gandy et al., 1995; Anderson et al., 
1998). Another study found that apoE may not be required for the maintenance of the 
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basal forebrain cholinergic neurons, but it may play a role in their repair following brain 
injury (Fagan et al., 1998). The reason for the discrepancy is not clear; however, 
differences in the strain, age, and sex of mice used may have contributed to the data 
inconsistencies. 
In contrast to the morphological studies, behavioral studies have consistently 
shown that the apoE-KO animals exhibit spatial learning deficits (Masliah et al., 1996; 
Gordon et al., 1996). Infusion of recombinant apoE into the lateral ventricles of apoE 
KO mice reversed behavioral and morphological anomalies (Masliah et al., 1996). Other 
studies involving apoE KO mice have suggested that apoE may be involved in protecting 
the brain against acute injury (Chen et al., 1997). These results provide convincing 
evidence that apoE plays a critical role in neuroprotection, preservation and plasticity 
within the CNS. 
Evidence Linking apoE to Alzheimer's Disease 
Increased apoE immunoreactivity is present in the brains of patients with such 
neurological diseases as Creutzfeldt-Jacob disease, Down's syndrome and Alzheimer's 
disease (AD) (Namba et al., 1991). In addition a recent study suggest the apoE4 allele 
may be involved with the onset of Parkinson's disease (Zareparsi et al., 2002). 
AD is characterized by the presence of senile (neuritic) plaques, amyloid 
angiopathy, and neurofibrillary tangles (Cotran et al., 1999). The neuritic plaques are 
focal, spherical collections of dilated, tortuous, silver-staining neuritic processes 
( dystrophic neurites) surrounding a central amyloid core, often surrounded by a clear 
halo. The dominant component of the plaque core is amyloid beta, a peptide of 
approximately 40-to 43-amino acid residues derived from a larger molecule, amyloid 
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precursor protein (APP) (Cotran et al., 1999). The neuritic components often colocalize 
with both APP and growth associated protein (GAP) 43, suggesting that they may 
represent aberrant sprouting of neurons (Masliah et al., 1992). Neurofibrillary tangles are 
intracellular and contain paired helical filaments along with some straight filaments that 
appear to have comparable composition. These filaments are composed of 
hyperphosphorylated tau (Cotran et al., 1999). ApoE fragments have been shown to 
induce intracellular neurofibrillary tangles in cultured neurons with truncated apoE4 
inducing more inclusions than truncated apoE3 (Huang et al., 2001 ). The deposition of 
tau in the brains of Alzheimer's disease patients is related to the amount of Abeta40 and 
the presence of apoE4 allele (Mann et al., 2002). The role of the plaques and tangles in 
the etiology of AD is still unclear. 
There are three forms of AD: early-onset familial, late-onset familial, and late-
onset sporadic. Early-onset AD represents approximately 5% of patients, whereas late-
onset AD accounts for a majority of AD cases. Accumulating data demonstrates a strong 
association of the apoE4 allele with late-onset familial AD (Corder et al., 1993; Mayeux 
et al., 1993; Rebeck et al., 1993; Sanders et al., 1993). The apoE4 allele is greatly over-
represented in late-onset familial AD subjects (52%) versus controls (16%), and the risk 
of AD in individuals homozygous for apoE4 is over five times that of homozygous apoE3 
individuals (Coder et al., 1993). Moreover, AD patients with apoE4 alleles usually show 
an earlier age of onset and a more rapid progression of the disease (Bennet et al., 1995). 
These findings suggest a causal link between apoE polymorphism and the development 
of AD; again, the mechanism behind the pathological effects of the apoE polymorphism 
remains unknown (Roses et al., 1994). 
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Effect of apoE on Neurite Outgrowth 
Previous findings suggest that apoE4 may contribute to AD by inhibiting neurite 
outgrowth (Bellosta et al., 1995; Mahley et al., 1996; Nathan et al., 1994; Nathan et al., 
1995). Incubation of primary dorsal root ganglion neurons or Neuro-2a cells, a murine 
neuroblastoma cell line, with apoE3 or apoE4 together with either plasma lipoproteins or 
CSF lipoproteins, resulted in dramatic isoform-specific effects. In both neuronal cell 
culture systems, apoE3 increased neurite outgrowth, whereas apoE4 stunted outgrowth 
(Nathan et al., 1994; Nathan et al., 1995). In these studies, the apoE isoforms also 
affected the cytoskeleton. Cells treated with lipoproteins and apoE4 showed fewer 
microtubules as compared with cells grown in medium alone, in medium containing 
lipoproteins, or in medium containing lipoproteins and apoE3 (Nathan et al., 1995). 
These effects of apoE on neurite outgrowth appear to be lipoprotein receptor-mediated. 
Free apoE, which is not a ligand for lipoprotein receptors, does not mediate the effect in 
the absence oflipoproteins (Bellosta, 1995; Nathan et al., 1995). The in vitro data 
therefore demonstrate that apoE has a tremendous impact on the structure and function of 
cultured PNS neurons. 
Basic Structure of the Olfactory System 
The olfactory epithelium is made up of an epithelium and a mucosal layer (figure 
1). The olfactory receptor neurons (ORN) reside in a pseudostratified epithelium on the 
nasal turbinates. Basal cells lie at the base of the epithelium and are critical because they 
divide and form new olfactory neurons. Sustentacular cells are distributed throughout the 
epithelium. They help detoxify chemicals that come into contact with the epithelium. 
The axons from the olfactory neurons collect in bundles and form the olfactory nerve. 
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The nerve exits the nasal cavity, passes through the cribriform plate, and terminates in the 
glomeruli of the olfactory bulb. 
The olfactory bulb develops from the telencephalon, and is, therefore, a part of the 
cerebral hemispheres. It is the first CNS relay for olfactory input. The bulb is organized 
in concentric laminae each with characteristic cell types and synaptic connectivity (figure 
2). The most peripheral layer is the olfactory nerve layer. It is composed of the axons of 
the ORN, sheathing glia and microglia. The olfactory receptor axons terminate in the 
glomerular layer, synapsing on the dendrites of mitral cells in structures termed 
glomeruli. Internal to the glomerular layer is the external plexiform layer, which is a cell 
poor zone containing the dendrites of mitral cells and other interneurons. The cell bodies 
of the mitral cells, the principal projection neurons of the olfactory bulb, are located in a 
distinct monolayer between the external plexiform layer and granular cell layer. The 
granular cell layer is principally composed of small interneurons, called granule cells, 
whose dendrites ramify in the external plexiform layer. Apart from the granule cells, the 
bulb also contains two other interneurons, tufted cells, in the external plexiform layer, 
and periglomerular cells, surrounding the glomeruli. 
Olfactory Nerve Regeneration 
Verhaagen and coworkers induced reversible lesions of the olfactory epithelium 
and olfactory nerve with Triton X-100 (TX-100) and characterized the process of 
regeneration in mice (Verhaagen et al., 1989; Verhaagen et al., 1990). Intranasal 
irrigation ofTX-100 in mice causes rapid retrograde degeneration of the ORN in the 
epithelium, with orthograde degeneration of their synaptic terminals in the bulb while 
sparing the basal cells. The degenerative process is completed during the first week 
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following lesioning. V erhaagen and coworkers identified two stages in the regeneration 
process of olfactory neurons. The first stage starts with the basal cells proliferating at 
about three days post-lesioning. These newly formed neurons expressed GAP 43, a 
phosphoprotein related to neuronal growth and plasticity. New axons reach the olfactory 
nerve layer at one to two weeks, and at three weeks, neurons are visible in the glomeruli. 
The second stage begins when the neurons reach the glomeruli. This stage is marked by 
a decrease in the expression of GAP43 and an increase in the expression of olfactory 
marker protein (OMP), a protein of unknown function present only in mature neurons. 
The entire process is complete at six to seven weeks (Cummings et al., 2000). 
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Goals and Hypotheses 
I. To examine the distribution of apoE in the mouse olfactory bulb. I hypothesized 
that apoE would be expressed in areas of nerve degeneration and regeneration. 
2. To examine the distribution of apoE in the olfactory bulb following olfactory 
nerve lesion. I hypothesized that apoE would be transiently increased following 
olfactory nerve lesion. 
3. To examine the effects of apoE deficiency in olfactory nerve regeneration. I 
hypothesized that apoE deficient mice would have delayed olfactory nerve 
regeneration as compared to wild type mice. 
4. To investigate the effects of human apoE4 and human apoE3 genes in olfactory 
nerve regeneration. I hypothesized nerve recovery would follow the order: 1. 
wild-type, 2. apoE3, 3. apoE4, 4. apoE-KO. 
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EXPERIMENT I: APOLIPOPROTIEN E IMMUNOREACTIVITY IN MOUSE 
OLFACTORY BULB 
Materials and Methods 
To examine the distribution of apoE-like immunoreactivity in mice, wild-type 
(WT) and apoE KO mice (C57BL/6J, males, 4 months old) were purchased from 
Jackson, Bar Harbor, ME. Mice were anesthetized with sodium pentobarbital (80 
mg/kg), transcardially perfused with cold saline (0.9°/o NaCl) and then with 4% 
paraformaldehyde in 0.1 M phosphate buffered saline, pH 7.4 (PBS). Olfactory bulbs 
were removed and post-fixed in buffered :fixative for two hours. Following the :fixation, 
olfactory bulbs were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer. 
After cryoprotection, the bulbs were frozen with dry ice and sections were cut on a 
cryostat at 30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h, then 
incubated for 48 h with anti-apoE polyclonal goat primary antisera (Calbiochem) at 
1:16,000 dilution in PBS. The sections were then incubated in rabbit-anti-goat solution 
(1 :200 dilution; Cappel) for 1 h, rinsed three times with PBS, then peroxidase-anti-
peroxidase complex (1: 100 dilution; Sternberger) for 1 h. The immunoreactive product 
was nickel-intensified (Benzing et al., 1995). Diaminobenzidine (DAB) (0.05% with 
0.01% ofH202) was used directly for development. ApoE KO mice were processed in 
parallel with normal mice. 
Results 
ApoE-like immunoreactivity was clearly present in the mouse olfactory nerve 
layer, where the large fascicles of olfactory nerve were often, but not always, outlined by 
immunoreactive product (figure 3, A and B). Cellular processes could be consistently 
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seen in the olfactoiy nerve and these appeared to be glial, although the type of glia was 
not ascertained. Glomeruli were weakly immunostained, but were clearly outlined by 
reaction product in the septae surrounding the glomeruli (figure 3, A and B). 
Jmmunostaining was in cellular processes of what appear to be glai although a neuronal 
source was not ruled out. Immunoreactivity in this periglomerular region was more 
intense than in the EPL. The EPL, although less intensely immunostained that the 
periglomerular region, did display lamination with the external part adjacent to glomeruli 
more immunoreactive that the internal part. The internal plexiform layer, just beneath the 
mitral cell layer, was obviously stained more intensely than the EPL or GCL. In addition, 
the core of the subependymal layer was intensely immunostained. A complete absence of 
staining in the apoE KO mice confirmed that we were visualizing apoE-like 
immunoreactivity. 
Discussion 
This study identifies apoE-like immunoreactivity surrounding olfactoiy nerves 
and glomeruli in normal olfactoiy bulbs in mice. Glia in this active region elaborate both 
trophic and inhibitory growth factors (Ramon-Cueto et al., 1995). Moreover, glia 
probably participate both in the recycling of membrane constituents of degenerating 
olfactory nerve fibers and the facilitation of axonal elongation and neuropil 
reorganization associated with regeneration. Therefore, apoE present in this region may 
be involved with either degeneration or regeneration of axons. 
The distribution of olfactoiy bulb apoE is not spatially congruent with GAP43 
which is a 25 kD protein that is associated with axonal growth cones and preterminal 
axons in the olfactoiy bulb (Ramakers et al., 1992; Verhaagen et al., 1989). Both the 
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glomerular zone and granule cell layer are rich in GAP43 immunoreactivity (Ramakers et 
al., 1992; Struble et al., 1998; Verhaagen et al., 1989), but apoE is primarily found in the 
gtomerular zone with markedly less immunoreactivity present in the granule cell layer. 
This observation suggests that apoE is not simply related to axonal growth. The olfactory 
bulb might be an ideal structure for determining the role of apoE in regeneration or 
degeneration in light of the ability of the olfactory nerve to regenerate and the availability 
to reversibly lesion the nerve. 
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EXPERIMENT II: APOLIPOPROTEIN EIS UPREGULATED IN OLFACTORY 
BULB GLIA FOLLOWING PERIPHERAL RECEPTOR LESION IN MICE 
Material and Methods 
Two- to four-month-old C57BL/6J mice (Jackson, Bar Harbor, ME) were 
lesioned as previously described (Margolis et al., 197 4; Rochel et al., 1980; Verhaagen et 
al., 1989). Briefly, a 25-gauge needle with a rounded tip, was inserted approximately 2 
mm into one nostril, and 100 µl of 0. 7 % TX-100 in saline, or 100 µl of saline alone was 
irrigated into a nostril of unanesthetized mice. This technique results in extensive 
bilateral damage to the olfactory epithelium with approximately 70-800/o of the olfactory 
epithelium lesioned (Nathan and Struble, personal observation). This procedure spares 
the basal cells which subsequently divide and differentiate into new ORN (Margolis et 
al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Mice were sacrificed at days 0, 3, 
7, 14, 28, 44 and 56 days post-treatment (n=3 mice treated with TX-100 at each time 
point and one mouse at each time point treated with saline alone). 
Following the survival periods after TX-100- or saline-irrigation, mice were 
anesthetized with pentobarbital (80mg/kg), and perfused transcardially with cold saline 
and then with 4% paraformaldehyde in 0.1 M PBS, pH 7.4. Olfactory bulbs were 
removed and post-fixed in buffered fixative for two hours. Following the fixation, 
olfactory bulbs were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer. 
After cryoprotection, the bulbs were frozen with dry ice and sections were cut on a 
cryostat at 30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h, then 
incubated for 48 h with anti-apoE polyclonal goat primary antisera (Calbiochem) at 
1: 16,000 dilution in PBS. The sections were then incubated in rabbit-anti-goat solution 
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(1 :200 dilution; Cappel) for 1 h, rinsed three times with PBS, then peroxidase-anti-
peroxidase complex (1 :200 dilution; Sternberger) for 1 h. The immunoreactive product 
was nickel-intensified (Benzing et al., 1995). DAB (0.05% with 0.01% ofH202) was 
used directly for development. 
To determine the glial cell type expressing apoE, double label 
immunocytochemistry was performed on olfactory bulb sections obtained from mice 
sacrificed at three and seven days post-nerve lesion or saline treatment. This double 
labeling technique uses sequential reactions with antisera and reaction products of DAB 
and benzidine dihydrochloride (BDHC) (Levey et al., 1986). In our hands BDHC is not 
nearly so sensitive as DAB as a chromogen, however, we purposely selected chromogens 
that were easy to discriminate. DAB results in a diffuse brown product and BDHC 
presents a granular blue reaction product. Hence, we could identify colocalization on the 
basis of both color and appearance. Although probably less sensitive than other 
techniques, the granular deposition of BDHC allowed unequivocal identification of cell 
types expressing apoE. Sections were initially processed for demonstrating apoE with 
goat antisera at 1 :8 000 dilution overnight followed by rabbit-anti-goat serum (1 :200 
dilution; Cappel) and then goat peroxidase-anti-peroxidase (1 :200 dilution; Sternberger). 
DAB (0.05% with 0.01% ofH202) was used directly for development. Some sections 
were removed and mounted directly on slides. The remainder of the sections were 
reacted overnight with either monoclonal anti- mouse F4/80 (1 :400 dilution; Serotec), an 
antigen expressed by activated microglia, (Andersson et al., 1991) or monoclonal 
antibody to GFAP (1:4,000 dilution, Accurate). These sections were then developed with 
0.01% BDHC. The following controls were included to assure specificity (Levey et al., 
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l986). 1) Sections were immunoreacted for the initial antigen (apoE), developed with 
DAB then reacted with BDHC in the absence of the secondary antibody. 2) The initial 
jmmunohistochemical steps to visualize apoE were omitted, the sections were reacted 
with DAB, and then the sections were immunoreacted for the second antigen (either 
F4/80 or GFAP). Changing the order of antisera (i.e., reacting first for GFAP or F4/80) 
was not feasible because the BDHC technique was not sensitive enough to reliably 
identify apoE immunoreactive perikarya in unlesioned mice. 
To determine the distribution of apoE immunostained cells, sections form at least 
two mice, at ages up to 14 days, were reacted with DAB as the chromogen. Plotting of 
apoE-immunostained cells in these sections was performed with Neurolucida, which 
permits operator selection of marked objects on a live microscopic image. The lamina 
were outlined at low power (2x objective) then each immunostained perikarya was 
marked at higher power (20x objective). Areas of the section and cell counts were used 
to obtain a rough estimate of cell density. 
Results 
lmmunocytochemical studies of saline treated mice displayed the previously 
described distribution of apoE-like immunoreactivity (Struble et al., 1999). Most apoE 
immunoreactivity in saline treated mice was diffusely present in the neuropil, primarily 
surrounding glomeruli. Few apoE immunoreactive cell bodies were visible and most of 
these were found in the glomerular layer (figure 4). Three days following TX-100 lesion, 
the olfactory nerve showed intense immunostaining for apoE although the glomeruli 
displayed about the same intensity ofimmunostaining as in the control mice (figure 5). 
Seven days following lesion, apoE continued to show intense staining in the olfactory 
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nerve and also showed glomerular immunoreactivity (figure 6). At 14 days, apoE-like 
imJDunoreactivity increased in the glomeruli to bring intensity levels comparable to that 
of the external plexiform layer (figure 7). By 28 days post-lesion, the apoE 
immunoreactivity was similar the non-lesioned mice (figure 8). 
Colocalization studies at three and seven days following lesion showed that apoE 
was expressed by both astroglia expressing GF AP and microglia expressing 
immunoreactivity identified by F4/80 (figure 9). The granular/crystalline BDHC reaction 
product ofGFAP or F4/80 was commonly associated with depositions of the more 
uniform DAB reaction product representing apoE. These observations show that both 
astroglia and microglia are associated with apoE. 
Plotting of apoE-immunoreactive cells generally supported these conclusions. 
Although only two sections were available for each time period, the pattern was virtually 
identical between the sections at each age. In saline treated mice the density of visible 
apoE immunoreactive cells was about l 8/mm2 and theses cells were primarily in the 
glomerular layer. At three days after lesion immunoreactive cell bodies could be seen 
throughout the olfactory bulb including the external plexiform and granule cell layer. In 
this case, the density ofidentifiable cells was 253/mm2. The cells containing apoE-like 
immunoreactivity appeared to be glia. At seven days, the olfactory nerve had 
degenerated, and apoE immunoreactive somata were seen primarily in the periglomerular 
region and a rough density of l l 9/mm2. By 14 days, overall immunostaining for apoE-
like immunoreactivity appeared to be increased throughout the olfactory bulb and density 
in this section was 27 /mm2. Most of these immunoreactive perikarya were present in the 
glomerular layer. By 42-56 days, no differences in the numbers of visible cells could be 
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seen between the control and lesioned mice. At no time did we observe apoE-like 
iJDmunoreactivity in unequivocally recognized neurons. 
Discussion 
Degeneration and regeneration in the olfactory bulb following olfactory nerve 
lesion in this study replicates previous reports in mice (Rochel et al., 1980; Verhaagen et 
al., 1990; Graziadei et al., 1983; Harding et al., 1977; Nadi et al., 1981; Verhaagen et al., 
1989) and rats (Schwob et al., 1995; Ravi et al., 1997; Deamer et al., 1995; Genter et al., 
1994). OMP in the olfactory bulb declines slightly at three days following olfactory 
epithelium lesion, and fully by seven days, representing the degeneration of the ORN 
terminals. Olfactory nerve terminals were still present in the glomeruli at three days and 
immunoreact for either amyloid precursor protein-like immunoreactivity (Struble et al., 
1998) or OMP (Struble and Nathan, personal observation). Within several days, the 
olfactory epithelium begins to regenerate from stem cells (Schwob et al., 1995; Graziadei 
et al., 1979). Progeny of these stem cells differentiate into new ORN, and grow axons 
into olfactory bulb to re-innervate glomeruli between 14 to 21 days (Schwob et al., 1999). 
Consequently these studies provide a framework for analyzing apoE expression in the 
temporal sequence of events in the regeneration process. 
ApoE elevation is correlated with olfactory nerve degeneration and regeneration. 
lmmunocytochemical observations of intense apoE-like immunoreactivity on the nerve 
and an increased number of visible perikarya in the glomerular layer support this 
interpretation. Glomeruli were only weakly immunoreactive at 3 days, when fibers are 
still present in the glomeruli (Struble et al., 1998), but intensity had increased by seven 
days and apoE levels were still elevated at 21 days. This pattern of apoE expression is 
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basically the reverse of OMP expression in the bulb following olfactory epithelium 
lesion. As OMP levels recovered, apoE levels declined. 
Plotting of apoE immunoreactive perikarya raise several interesting questions, 
although these studies were not designed to rigorously evaluate density. Increased 
numbers of immunoreactive perikarya are seen throughout the olfactory bulb and total 
cell number is 10-fold that in control tissue at three days. In contrast, total apoE (by 
western blot) is only 2 fold of saline treated levels (Nisar, 1999). Furthermore, whole 
bulb levels of apoE remain elevated for 14 to 21 days, but the plotting results show that 
the number of visible apoE-immunoreactive perikarya rapidly decline to essentially 
normal levels by 14 days. 
Part of the explanation for this discrepancy may be in the difficulty of localization 
of apoE. In our hand, apoE immunoreactivity in the nonnal mice olfactory bulb is 
diffuse; visible apoE-immunoreactive perikarya were very rare. Procedures to increase 
the intensity of perikaryal staining also raised the "background" similarly, suggesting that 
apoE immunoreactivity is primarily present either in small processes or extracellularly. 
This discrepancy between the density of apoE immunoreactive cells and whole bulb 
immunoreactivity probably represents the localization of apoE in the neuropil. These 
data suggest that initially glia produce apoE (hence a perikaryal localization) but it is 
rapidly translocated to an extracellular compartment. Neurons apparently are not a major 
source for apoE production. The mitral neurons are found in single laminae in the bulb 
and it is highly unlikely that we would not have seen a labeled cell. This suggests that 
intraneuronal apoE concentration in vivo is below the threshold of detectability by 
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jmmunocytochemical techniques. Hence, neuronal translocation of apoE and associated 
lipids is comparatively small or brief 
Translocation apparently occurs in the PNS. Resident macrophages and 
monocyte-derived macrophages, at the site of injury, are reported to be the primary 
sources of the large quantities of apoE-containing lipoproteins (Boyles et al., 1985). 
These lipoprotein particles probably scavenge cholesterol released from degenerating 
myelin. Scavenged cholesterol was subsequently used in membrane biosynthesis by 
growth cones of sprouting axons by the low-density lipoprotein (LDL) receptor-mediated 
endocytosis (Mahley, 1988). Reactive gliosis in the CNS may by a central equivalent of 
macrophage activity in the PNS. 
Reactive gliosis appears to parallel apoE expression. Several studies have 
reported intense reactive astrogliosis within three to seven days of nerve lesion both 
around olfactory glomeruli and also throughout the olfactory bulb (Schwob et al., 1999; 
Struble et al., 1999; Deamer et al., 1995; Anders et al., 1990). Furthermore astroglial 
markers are elevated in the olfactory bulb for at least 2 to 4 weeks following lesion. 
These data suggest that processes related to degeneration continue for several weeks 
following nerve lesion. A previous study suggested that apoE might be involved in 
regeneration because hippocampal elevation of apoE mRNA trail that of GF AP following 
perforant path lesion (Poirier et al., 1991). These data are not contradictory. If astroglia 
and microglia must be activated before they produce apoE, this temporal relationship is 
logical. 
The double labeling immunocytochemical studies confirmed that both reactive 
astroglia and microglia produce amounts of apoE following a lesion. It is probably fairly 
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safe to further suggest that apoE is produced by activated microglia. In vitro studies have 
shown apoE production by microglia, but in vivo studies have been equivocal (Boyles et 
al., 1985; Nakai et al., 1996; Uchihara et al., 1995; Fujita et al., 1999). This difference 
may represent a detection problem perhaps related to the "activated" status of astroglia 
and microglia. I was unable to unequivocally colocalize apoE and the microglail marker 
in non-lesioned mice, although I did identify GF AP-apoE co-localization in the same 
mice. Only following olfactory nerve lesion, when whole bulb levels of apoE increased 
1.5 to 2-fold was the level of apoE high enough to detect when I used combined labeling 
with DAB and BDHC. Nonetheless, it would seem logical that detection of apoE in 
microglia may require up-regulation of both microglial antigen (F4/80) that occurs after 
lesion (Anderssen et al., 1991) and cellular localization of apoE. Our data show that both 
microglia and astroglia produce apoE in the olfactory bulb but activation of glia might be 
required for co-localization. 
A hypothesis of injury-induced apoE production may explain variable 
morphological effects observed in the absence of the apoE gene. In vitro, apoE, but only 
in combination with a source oflipids, facilitates process growth (Nathan et al., 1994). I 
propose that in vivo apoE is transiently increased to scavenge lipids released form 
degenerating processes, and then provides those lipids to regenerating processes. Much 
of this lipid is postulated to come from degenerating myelin sheaths (Mahley et al., 
1996). In the intact central nervous system, inefficient recovery may not be apparent, or 
perhaps could be compensated for by other less efficient apolipoproteins (Terrisse et al., 
1998). 
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A hypothesis of apoE participation in lipoprotein recycling is also compatible 
with previous observations of the effects of apoE alleles in both AD and recovery form 
bead injury. The apoE4 allele not only predisposes to AD, but also substantially 
increases the risk of developing AD after head trauma (Mayeux et al., 1995). Moreover, 
patients with the apoE4 allele manifest a poorer outcome following traumatic brain injury 
(Jordan et al., 1997), and boxers with the E4 allele were at much greater risk to develop 
chronic neurologic deficits than those not having the E4 allele (Jordan et al., 1997). 
Recently, it was suggested that blood-flow (measured by £MRI) in individuals with 
apoE4 allele may be greater than apoE3 homozygotes while performing the same task 
(Bookheimer et al., 2000) suggesting some level of inefficiency in learning. If apoE is 
involved in efficient recycling or redistribution of lipoproteins during brain function or 
following injury, a lifetime of inefficient functioning may results in an accentuation of 
mild dysfunction and an increased risk for dementia. 
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EXPERIMENT ill: DELAYED OLFACTORY NERVE REGENERATION IN 
APOE-DEFICIENT MICE. 
Materials and Methods 
Breeding pairs of homozygous apoE KO mice that have been back-crossed at 
least 10 times to the C57BL/6J wild-type mice (Jackson, Bar Harbor, ME). ApoE 
genotype of the litters were verified by PCR and confirmed by immunoblot using anti-
apoE (1: 1000; Calbiochem). 
Two- to four-month-old apoE KO and wild type mice were lesioned as previously 
described (Margolis et al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Briefly, a 
25-gauge needle with a rounded tip, was inserted approximately 2 mm into one nostril, 
and 100 µl of0.7% TX-100 in saline or 100 µl of saline alone was irrigated into a nostril 
of unanesthetized mice. This technique results in extensive bilateral damage to the 
olfactory epithelium with approximately 70-80% of the adult olfactory epithelium 
lesioned (Nathan and Struble, personal observation). This procedure spares the basal 
cells, which subsequently divide and differentiate into new ORN (Margolis et al., 1974; 
Rochel et al., 1980; Verhaagen et al., 1990). Mice were sacrificed at days 0, 3, 7, 14, 21, 
42 and 56 days post-treatment (n=3 animals for each time point and treatment). 
Following the survival periods after TX-100 or saline irrigation, mice were 
anesthetized with pentobarbital (80 mg/kg), and perfused transcardially with cold saline 
and then with 4% paraformaldehyde in 0.1 M phosphate buffer. Olfactory bulbs were 
post-fixed in buffered fixative for two hours. Following the fixation, olfactory bulbs 
were cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer. After 
cryoprotection, the bulbs were frozen with dry ice and sections were cut on a cryostat at 
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30 µm. Sections were incubated in 5% dried milk in 0.1 M PBS for 1 h. Sections were 
then incubated for 48 h with anti-OMP polyclonal goat primary antisera (gift from Frank 
Margolis, Ph.D., University of Maryland) at 1 :4,800 dilution in PBS. The sections were 
then incubated in rabbit-anti-goat solution (I :200 dilution; Cappel) for 1 h, rinsed three 
times with PBS, then goat peroxidase-anti-peroxidase complex (1:200 dilution; 
Sternberger) for 1 h. DAB (0.05% with 0.01% ofH202) was used directly for 
development. 
Results 
OMP 
Day 3 Saline Treated: The WT-SA and KO-SA mice both showed intense 
immunoreactivity in the olfactory nerves and the glomerular layer. No differences were 
seen between the two groups. 
Day 3 TX-100 Treated: The WT-TX mice (figure 10) and KO-TX mice (figure 11) 
showed intense immunoreactivity in the olfactory nerves. The WT-TX mice showed 
moderate immunoreactivity in the glomerular layer while the KO-TX mice showed light 
staining in the glomerular layer. 
Because the WT-SA and KO-SA mice both showed the typical immunoreactivity 
seen in untreated WT mice, we decided not to immunostain the WT-SA mice on days 7, 
21and56. 
Day 7 Saline Treated: The KO-SA mice showed intense immunoreactivity in the 
olfactory nerve and glomerular layer. This immunoreactivity was the same as the KO-SA 
and WT-SA mice further supporting our idea not to stain the WT-SA mice on days 7, 21 
and 56. 
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Day 7 TX-100 Treated: The WT-TX mice showed intense immunoreactivity in the 
olfactory nerve and moderate immunoreactivity in the glomerular layer. The KO-TX 
mice showed light to moderate immunoreactivity in the olfactory nerve and glomerular 
layer. 
Day 21 Saline Treated: The KO-SA mice showed dark olfactory nerve immunoreactivity 
and moderate, well organized glomerular immunoreactivity. 
Day 21 TX-100 Treated: The WT-TX mice (figure 12) showed strong immunoreactivity 
in the olfactory nerve and moderate immunoreactivity in the glomerular layer. The 
glomeruli were decreased in number but appeared well organized. The KO-TX mice 
(figure 13) had moderate immunoreactivity in the olfactory nerve and glomerular layer; 
however, the glomeruli were unorganized. 
Day 42 Saline Treated: All of the 42-day mice were overall lightly staining. The WT-SA 
and KO-SA showed light immunoreactivity in the olfactory nerve and glomerular layer. 
Day 42 TX-100 Treated: The glomeruli in the WT-TX mice were not as numerous as in 
the saline treated mice; however the immunoreactivity was the same. The KO-TX mice 
showed light immunoreactivity in the olfactory nerve, similar to the other 42-day mice. 
The glomerular layer was also lightly stained, but the glomeruli were smaller compared 
to the other 42-day mice. 
Because the 42-day WT-TX mice showed almost complete recovery from 
olfactory nerve lesion, no WT mice were stained on day 56. 
Day 56 Saline Treated: All of the 56-day mice were overall lightly staining. The KO-SA 
mice showed a light immunoreactivity in the olfactory nerve and glomerular layer. In 
addition, the glomeruli were small and unorganized. 
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Day 56 TX-I 00 Treated: The KO-TX mice showed light staining in the olfactory nerve 
and glomerular layer. Similar the 56-day KO-SA mice, the glomeruli were unorganized. 
In addition, the glomeruli were sparse and incompletely stained. 
Discussion 
On days 3 and 7, there was a loss ofOMP immunoreactivity. This represents 
degeneration of olfactory nerve after lesion. By day 21, there was an increase in OMP 
immunoreactivity in the WT-TX mice. This reactivity showed that some of the axons 
had already reached the glomerular layer. The KO-TX mice did not have the same 
immunoreactive pattern as the WT-TX mice. KO-TX mice did not show the same 
pattern of mature olfactory neurons in the glomerular layer, as seen by OMP 
immunoreactivity. By day 42 the WT-TX mice appeared to be almost fully recovered 
from the lesion. In comparison the KO-TX mice had not recovered. OMP 
immunoreactivity was still poor at 56-days in the KO-TX mice representing a lack of 
neurons reaching the glomerular layer and forming mature synapses. In conclusion, it 
appeared that the absence of an apoE gene greatly diminishes the ability of the olfactory 
nerve to regenerate following lesion. 
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EXPERIMENT IV: EFFECTS OF HUMAN APOLIPOPROTEIN E ISOFORMS 
ON OLFACTORY NERVE PLASTICITY IN MICE 
Materials and Methods 
Two- to four-month-old male WT, apoE KO and transgenic mice (gift from David 
Holtzman, M.D., Washington University) were used for this study. The transgenic mice 
were apoE KO mice that had either a human apoE3 gene or a human apoE4 gene inserted 
under a GFAP promoter (Sun et al., 1998). Mice were lesioned as previously described 
(Margolis et al., 1974; Rochel et al., 1980; Verhaagen et al., 1990). Briefly, a 25-gauge 
needle with a rounded tip, was inserted approximately 2 mm into one nostril, and 100 µl 
of0.7 % TX-100 in saline, or 100 µl of saline alone was irrigated into a nostril of 
unanesthetized mice. This technique results in extensive bilateral damage to the olfactory 
epithelium with approximately 70-800/o of the adult olfactory epithelium lesioned (Nathan 
and Struble, personal observation). This procedure spares the basal cells which 
subsequently divide and differentiate into new ORN (Margolis et al., 1974; Rochel et al., 
1980; Verhaagen, et al., 1990). 
Mice were sacrificed at 14 days post-treatment which is the midpoint of olfactory 
nerve regeneration (n=3 mice for each genotype and treatment). Mice were anesthetized 
with pentobarbital (80 mg/kg), and perfused transcardially with cold saline and then with 
4% paraformaldehyde in 0.1 M phosphate buffer. Olfactory bulbs were post-fixed in 
buffered fixative for two hours. Following the fixation, olfactory bulbs were 
cryoprotected overnight in 300/o sucrose in 0.1 M phosphate buffer. After cryoprotection, 
the bulbs were frozen with dry ice and sections were cut on a cryostat at 30 µm. Sections 
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were incubated in 5% dried milk in 0.1 M PBS for 1 h. Each mouse olfactory bulb was 
assessed for five antigens as follows: 
1. Anti-GFAP monoclonal mouse antibody (1:4,000 dilution; Accurate) 48 h incubation 
2. Anti-apoE polyclonal goat antibody (1:8,000 dilution; Calbiochem) 24 h incubation 
3. Anti-F4/80 monoclonal mouse antibody (1 :400 dilution; Serotec) 24 h incubation 
4. Anti-OMP polyclonal goat antibody (1 :4,800 dilution; gift from Frank Margolis, 
Ph.D., University of Maryland) 24 h incubation 
5. Anti-Synaptophysin monoclonal mouse antibody (1:500 dilution; Boehringer 
Mannheim) 48 h incubation 
To visualize GFAP and Synaptophysin, sections were incubated in goat-anti-mouse 
solution (1 :200 dilution; Cappel) for 1 h, and for OMP and apoE, sections were incubated 
in rabbit-anti-goat solution (1 :200 dilution; Cappel) for 1 h. All sections were rinsed 
three times with PBS, then treated with either mouse or goat peroxidase-anti-peroxidase 
complex (1:200 dilution; Sternberger) for 1 h. DAB (0.05% with 0.01% H202) was used 
directly for development. An avidin/biotin (yectastain ABC kit, Vector) technique was 
used with DAB to visualize F4/80 binding. 
Results 
GFAP 
Saline Treated: No differences were seen between the WT-SA (figure 14), apoE3-SA, 
apoE4-SA and apoE-KO-SA groups. In general, immunoreactivity was more intense in 
the glomeruli. 
TX-100 Treated: The WT-TX (figure 15) and apoE-KO mice (figure 16) showed heavy 
immunoreactivity in the glomerular layer as well as a general increase in 
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immunoreactivity in the olfactory bulb. ApoE3-TX and apoE4-TX mice (figure 17) 
demonstrated immunoreactivity in the glomerular layer, but lacked the increased 
immunoreactivity in the external plexiform layer characteristic of the WT-TX and apoE-
KO mice. 
Summary: Following lesion GFAP-immunoreactivity in apoE3-TX and apoE4-TX mice 
did not appear to be increased throughout the bulb so much as it did in the WT-TX and 
apoE-KO mice. The absence of a normally regulated apoE gene affected expression of 
the GF AP gene. The failure to identify clear upregulation of immunoreactivity in the 
apoE3-TX and apoE4-TX mice may represent a ceiling effect or some interaction with 
the an abnormally regulated apoE gene. 
ApoE 
Saline Treated: The WT-SA mice (figure 18) showed diffuse immunoreactive pattern in 
the olfactory nerve and in the periglomerular layer, which, in turn showed more 
immunoreactivity than the glomerular layer. Only astroglial-like cell body staining in the 
glomerular layer was seen in the apoE3-SA and apoE3-SA mice (figure 19), and the core 
of the glomeruli were immunoreactive and darker than the rest of the bulb. There was no 
immunoreactivity in the KO-SA mice. 
TX-100 Treated: The WT-TX mice (figure 20) showed increased apoE immunoreactivity 
in the periglomerular layer. ApoE4-TX mice and apoE3-TX mice (figure 21) showed no 
increase in immunoreactivity. There was no immunoreactivity in the apoE-KO-TX mice. 
Summary: The levels of apoE are increased following lesion in the WT-TX mice; 
however, in the apoE3-TX and apoE4-TX groups apoE immunoreactivity is not increased 
following lesion. 
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F4/80 
Saline Treated: No differences were seen between the apoE-KO-SA, apoE3-SA, apoE4-
SA and WT-SA mice (figure 22). In general, there was moderate diffuse 
immunoreactivity in the glomerular layer and external plexiform layer with a lamination 
between these two layers. 
TX-100 Treated: The WT-TX mice (23) and apoE-KO-TX mice (figure 24) showed 
increased immunoreactivity in the glomerular layer and external plexiform layer 
compared to the transgenic mice (figure 25). 
Summaiy: The expression of either the apoE3 or apoE4 inserted gene apparently turns 
down or blocks activation of microglia. 
OMP 
Saline Treated: No differences were seen between the apoE-KO-SA , apoE3-SA, apoE4-
SA and WT-SA mice (figure 26). In general, the olfactory nerve and glomerular layer 
showed intense immunoreactivity. 
TX-100 Treated: Immunoreactivity in the WT-TX mice (figure 27) showed smaller 
glomeruli than in the SA treated mice. The apoE4-TX and apoE3-TX mice (figure 28) 
both showed less glomerular staining than the WT-TX mice. The KO-TX mice (figure 
29) showed less staining in the glomeruli than the transgenic mice. 
Summaiy: Recovery appeared to follow the order of WT-TX, apoE3-TX or apoE4-TX 
and apoE-KO-TX. Apparently the presence of either the apoE3 or apoE4 gene can 
partially compensate for the absence of the WT gene. 
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Synaptophysin 
Saline Treated: No differences were seen between the apoE-KO-SA, apoE3-SA, apoE4-
WT-SA mice (figure 30). In general, there is intense immunoreactivity in the glomerular 
layer and lighter immunoreactivity in the external plexiform layer. 
TX-100 Treated: The WT-TX mice (figure 31) had a general attenuation of 
immunoreactivity and smaller glomeruli compared to SA treated mice. Immunoreactivity 
in the apoE3-TX and apoE4-TX mice (figure 32) showed smaller and lighter glomeruli 
than seen in the WT-TX mice. The KO-TX mice (figure 33) had decreased 
immunoreactivity especially in the glomerular layer than the other treatment groups. 
Summary: Following lesion either apoE3 or apoE4 was adequate to produce some 
recovery of synaptophysin. 
Discussion 
The results of this study revealed that apoE deficiency in apoE gene KO mice 
leads to a delay in nerve recovery as compared to wild type mice. Expression of either 
human apoE3 or human apoE4 can partially compensate for the absence of the wild type 
gene. Nerve recovery appeared to follow the order: 1. wild type mice, 2. apoE3 
transgenic equivalent to apoE4 transgenic, and 3. ApoE-KO mice. 
In summary, the data suggest that apoE has a tremendous impact on neuronal 
plasticity. Furthermore, human apoE3 was found to be equivalent to apoE4 in supporting 
some degree of olfactory nerve repair in mice; however, neither was as good as the WT 
apoE gene, and both were better than apoE-KO mice. 
It is possible that the difference between apoE3 and apoE4 is just not 
distinguishable at two weeks, but would be distinguishable at three or more weeks post-
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lesion. It is possible that apoE3 has a favorable affect on olfactory nerve recovery, but at 
two weeks there are no differences. Therefore, the apoE3 gene mice might have 
complete recovery in six weeks post lesion and apoE4 gene mice might take a week or 
two longer for complete olfactory nerve recovery. ApoE4 may initially be able to handle 
the recovery, but at some point beyond two weeks, its ability to keep up the regenerative 
process may decrease. 
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Conclusions 
1. ApoE immuoreactivity surrounds the olfactory nerve and the glomeruli. This 
suggests that apoE may be involved with degeneration and regeneration. The 
olfactory bulb might be an ideal structure for determining the role of apoE in 
degeneration and regeneration of nerves. 
2. ApoE immuoreactivity increased in the olfactory nerve during degeneration 
following lesion and increased in the olfactory bulb during the regeneration 
process. ApoE is mostly produced by astrocytes, but also by microglia. 
3. The absence of an apoE gene diminished the ability of the olfactory nerve to 
recover following lesion. 
4. Transgenic apoE3 or apoE4 partially compensate for the absence of a wild type 
apoE gene, but neither was as good as the wild type gene. 
5. These studies all suggest that apoE has a tremendous impact on olfactory nerve 
recovery following lesion. 
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Figure 1. Olfactoiy epithelium and olfactoiy bulb. 
Figure 2. Lamina of the olfactoiy bulb. From outer to inner, olfactoiy nerve layer (onl), glomerular layer 
(glom), external plexiform layer (epl), mitral cell layer (arrows on left), internal plexiform layer (ipl), 
granule cell layer (gel) and ventricular layer (vent). 
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Figure 3 A and B. ApoE immunoreactivity present in olfactory nerve and glomerular layer. Low power 
view, arrowheads showing a lack ofimmunoreactivity in the mitral cell layer (ml) (A). High power view 
(B). 
Figure 4. ApoE immunoreactivity in the olfactory nerve (ON) and glomerular layer (G) in saline treated 
(N). 
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Figure 5. Intense apoE immunoreactivity in the olfacto:ry nerve three days post-lesion. Arrowhead 
pointing to olfacto:ry nerve. 
Figure 6. Increased apoE immunoreactivity in olfacto:ry nerve and glomerular layer seven days post-lesion. 
Arrowhead pointing to olfacto:ry nerve. 
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Figure 7. Increased apoE immunoreactivity in the glomerular layer at 14 days post-lesion. 
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Figure 8. ApoE immunoreactivity was similar to non-lesioned mice at 21 days post-lesion. 
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Figure 9. Double labeling of astroglia (A, C) and microglia (B, D) in the olfactoiy bulb at three days post-
lesion. Low power views of the gomerular layer show double labeling with DAB for apoE and BDHC 
(blue granular) labeling for either GF AP (A) or F4/80 (B). The large arrowhead in A and B identify the 
double-labeled perikarya shown in C and D. The smaller arrows represent apoE-producing cells not 
labeled with the BDHC. 
Figure 10. OMP immunoreactivity in WT-TX 
mice at three days post-lesion. Intense immuno-
reactivity in olfactoiy nerve and moderate 
reactivity in the glomeruli. 
Figure 12. OMP immunoreactivity in WT-TX 
mice at 21 days post-lesion. Intense 
immunoreactivity in olfactoiy nerve and 
moderate reactivity in the glomeruli. 
Figure 11. OMP immunoreactivity 
KO-TX mice at three days post-
lesion. Intense immunoreactivty 
In the olfactoiy nerve and moderate 
reactivity in the glomeruli. 
Figure 13. OMP immunoreactivty 
in KO-TX mice at 21 days post-
lesion. Intense reactivity in the 
olfactoiy nerve with unorganized 
glomeruli reactivity. 
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Figure 14. Wild-type, GFAP immuno-
reactivity, saline treated. Intense reactivity 
in the glomerular layer. All saline groups 
were similar. 
Figure 16. ApoE-KO, GFAP immuno-
reactivity, two weeks post-lesion. Intense 
reactivity in glomerular layer and an overall 
increase in reactivity. 
Figure 18. Wild-type, apoE immuno-
reactivity, saline treated. Diffuse reactivity 
in the olfactory nerve and glomerular layer. 
Figure 15. Wild-type, GFAP 
immunoreactivity, two weeks 
post-lesion. Intense immuno-
reactivity in the glomerular layer 
and an overall increase in reactivity. 
Figure 17. ApoE4, GFAP 
immunoreactivity two weeks 
post-lesion. Intense reactivity in 
the glomerular layer and an overall 
increase in reactivity. 
Figure 19. ApoE3, apoE immuno-
reactivity, saline treated. Astroglial-
like staining in the glomerular layer. 
ApoE4 was similar. 
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Figure 20. Wild-type, apoE immuno-
reactivity, two weeks post-lesion. 
Reactivity increased in olfactory nerve 
and glomerular layer. 
Figure 22. Wild-type, F4/80 immuno-
reactivity, saline treated. Moderate 
reactivity in the glomerular layer and 
external plexiform layer. All saline 
groups were similar. 
Figure 24. ApoE-KO, F4/80 immuno-
reactivity, two weeks post-lesion. 
Increased immunoreactivity in the 
glomerular layer and external plexiform 
layer. 
Figure 21. ApoE3, apoE immuno-
reactivity, two weeks post-lesion. 
No increase in reactivity. ApoE4 
was similar. 
Figure 23. Wild-type, F4/80 
immunoreactivity, two weeks post-
lesioin. Increased immunoreactivity 
in the glomerular layer and external 
plexiform layer. 
Figure 25. ApoE3, F4/80 immuno-
reactivity, two weeks post lesion. 
No increase in reactivity. ApoE4 
was similar. 
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Figure 26. Wild-type, OMP immuno-
reactivity, saline treated. Reactivity in 
the olfactory nerve and glomerular layer. 
All saline groups were similar. 
Figure 28. ApoE3, OMP immunoreactivity, 
two weeks post-lesion. Less glomerular 
reactivity than wild type mice. ApoE4 
was similar. 
Figure 30. Wild-type, Synaptophysin 
immunoreactivity, saline treated. Intense 
reactivity in the glomerular layer and 
external plexiform layer. All saline 
groups were similar. 
Figure 27. Wild-type, OMP 
immunoreactivity, two weeks post-
lesion. Gomeruli are smaller 
compared to saline treated mice. 
Figure 29. ApoE-KO, OMP 
immunoreactivity, two weeks post-
lesion. Less glomerular reactivity 
than the transgenic mice. 
Figure 31. Wild-type, Synaptophysin 
immunoreactivity, two weeks post-
lesion. Attenuation of reactivity and 
smaller glomeruli than saline treated 
groups. 
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Figure 32. ApoE4, Synaptophysin 
immunoreactivity, two weeks post-lesion. 
Smaller and lighter glomeruli than wild-
type mice. ApoE3 was similar. 
Figure 33. ApoE-KO, Synapto-
physin immunoreactivity, two weeks 
post-lesion. Decreased reactivity in 
glomerular layer compared to the 
wild type and transgenic lesioned 
mice. 
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